ŠPINAROVÁ, Lenka. Hypertenze po transplantaci srdce (Hypertension after heart transplantation). In Jiří Widimský jr., Jiří Widimský a kolektiv. Hypertenze. 4., rozš. a přeprac. vyd. Praha: Triton, 2014, p. 515-522. ISBN 978-80-7387-811-5.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Hypertenze po transplantaci srdce
Name (in English) Hypertension after heart transplantation
Authors ŠPINAROVÁ, Lenka (203 Czech Republic, guarantor, belonging to the institution).
Edition 4., rozš. a přeprac. vyd. Praha, Hypertenze, p. 515-522, 8 pp. 2014.
Publisher Triton
Other information
Original language Czech
Type of outcome Chapter(s) of a specialized book
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Publication form printed version "print"
RIV identification code RIV/00216224:14110/14:00077909
Organization unit Faculty of Medicine
ISBN 978-80-7387-811-5
Keywords in English Heart transplantation; hypertension; combination therapy; comorbidities
Tags EL OK
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 29/12/2014 12:37.
Abstract
Hypertenze je velmi časté komorbidita po transplantaci srdce. Má své patofyziologická specifika: srdeční denervace, využití cyklosporinu a kalcineurinového nefrotoxicity. Prvním krokem léčby by měla být snaha udržet nejnižší terapeutické hladiny cyklosporinu, předčasné ukončení prednisonu nebo přepnutí na takrolimus.
Abstract (in English)
Hypertension is a very common comorbidity after heart transplantation. It has its pathophysiological specificities: heart denervation, use of cyclosporine and calcineurin nephrotoxicity. There is no night blood pressure and heart rate decrease. The first step of treatment should be an effort to keep the lowest therapeutic level of cyclosporine, early termination of prednison or switch to tacrolimus. Antihypertensive therapy is mostly combination of drugs, the first choice should be inhibitors of angiotensin converting enzyme, angiotensin 2 receptor 1 blockers or calcium channel blockers. Long term acting drugs should be preffered.
PrintDisplayed: 7/10/2024 04:18